IFNA1 and neoplasm: Indeed, such combinations might help solve the issue of primary and secondary resistance to checkpoint inhibitors, which is associated with reduced IFN signaling and an immune-suppressive tumor phenotype, by activating type 1 IFN signaling and downstream adaptive antitumor immune mechanisms (42, 43).